Novartis licenses Array BioPharma's MEK inhibitors; terminated
Novartis Pharmaceuticals Corp. has licensed exclusive global rights to several of Array BioPharma Inc.'s (cancer, inflammation, and metabolic therapeutics) small-molecule MEK inhibitors, including Phase I ARRY162 for cancer and its back-up compound, ARRY300.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.